Physician profile
Vicki Rapaport
NPI 1851375604
$17,978.05
in general payments reported to CMS, 2019-2025
31 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $829 · 2021: $1,367 · 2022: $6,239 · 2023: $2,273 · 2024: $3,303 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,927 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,927.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,419.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,747.91 | 2019-2023 | |
| Abbvie INC. | $3,736.55 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,717.94 | 2019-2025 | Aklief, Oracea, Nemluvio |
| Incyte Corporation | $1,203.23 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $1,013.52 | 2022-2025 | Tremfya |
| Amgen INC. | $678.26 | 2020-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $677.13 | 2024-2025 | Daxxify, Daxi |
| Sun Pharmaceutical Industries INC. | $634.02 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Almirall LLC | $542.54 | 2019-2025 | Seysara, Klisyri |
| Ucb, INC. | $400.67 | 2021-2025 | Bimzelx |
| Pfizer INC. | $320.46 | 2019-2023 | |
| Leo Pharma INC. | $319.31 | 2019-2025 | Anzupgo, Adbry |
| Mayne Pharma Commercial LLC | $285.20 | 2019-2024 | |
| Lilly USA, LLC | $252.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Merz North America, INC. | $246.07 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $234.95 | 2022-2025 | |
| Celgene Corporation | $232.72 | 2019 | |
| Dermira, INC. | $198.24 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.79 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $96.41 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $69.39 | 2021-2023 | Libtayo |
| Journey Medical Corporation | $60.75 | 2020-2024 | |
| Epi Health, LLC | $39.45 | 2020 | |
| Dermavant Sciences, INC. | $31.94 | 2023 | Vtama |
| Novum Pharma, LLC | $23.85 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.06 | 2025 | Nuzyra |
| Aclaris Therapeutics, INC. | $20.21 | 2019 | |
| Organon LLC | $19.98 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $17.93 | 2019 | |
| Botanix Sb INC | $17.06 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Rapaport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.